Similarly, CSNK1D has recently been identified as a novel drug target in Hedgehog/GLI-driven cancers (Peer et al., 2021), and silencing of CSNK1D attenuates the migration and metastasis of triple-negative breast cancer cells (Bar et al., 2018). Here, GLI1 is linked to triple-negative breast carcinoma.